The number of people dying from liver disease or liver cancer related to chronic viral hepatitis C and B, fatty liver and alcohol continues to increase at an alarming pace. Of patients with cirrhosis and liver cancer, less than 25% receive routine liver cancer screening. Currently there are over 4,000,000 people with chronic hepatitis C and 2,000,000 people with chronic hepatitis B in the United States who can benefit from treatment. As a result of obesity, there are also about 2,000,000 people with Metabolic dysfunction-associated steatohepatitis (MASH) in the United States. 25-30% of patients with hepatitis C, hepatitis B, MASH or alcohol related liver disease have cirrhosis. Cirrhosis is the leading cause of liver cancer and liver failure.
In New Jersey there are over 300,000 people with hepatitis C, hepatitis B, MASH or alcohol related liver disease. Unidentified and untreated, the number of people diagnosed with liver cancer may double over the next 10-15 years. By 2025 MASH related cirrhosis will be the leading cause of need for liver transplant in the United States. By that time, there will be at least 2,500,000 people in the United States with cirrhosis. Current treatment of HCV allow 9 out of 10 patients to successfully be cured of their infection. Current treatment for hepatitis B controls the virus 100% of the time. Treatment of MASH will mostly depend on how we deal with the obesity epidemic. Treatment of alcohol over-use is an ongoing challenge.
At NJ Liver Care you are not a service line. You are a person with an illness of the liver that we are dedicated to fixing. For patients with cirrhosis, the goal is to help you live healthier and prevent liver cancer and liver failure.
Andrew N de la Torre MD, FACS, FAASLD
In New Jersey there are over 300,000 people with hepatitis C, hepatitis B, MASH or alcohol related liver disease. Unidentified and untreated, the number of people diagnosed with liver cancer may double over the next 10-15 years. By 2025 MASH related cirrhosis will be the leading cause of need for liver transplant in the United States. By that time, there will be at least 2,500,000 people in the United States with cirrhosis. Current treatment of HCV allow 9 out of 10 patients to successfully be cured of their infection. Current treatment for hepatitis B controls the virus 100% of the time. Treatment of MASH will mostly depend on how we deal with the obesity epidemic. Treatment of alcohol over-use is an ongoing challenge.
At NJ Liver Care you are not a service line. You are a person with an illness of the liver that we are dedicated to fixing. For patients with cirrhosis, the goal is to help you live healthier and prevent liver cancer and liver failure.
Andrew N de la Torre MD, FACS, FAASLD
Liver Disease & Cancer Care
Liver Pancreas and Biliary Surgery
at CarePoint Health
Phone: 201-420-7903 Fax: 201-420-7586
1 Journal Square Plaza
2nd floor
Jersey City NJ 07306
2nd floor
Jersey City NJ 07306
330 Grand St
Hoboken NJ 07030
Hoboken NJ 07030
654 Broadway
Bayonne NJ 07002
Bayonne NJ 07002